Veru earnings beat by $0.27, revenue fell short of estimates
- ByInvesting.com
- •
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for metastatic breast cancer and for viral acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor agonist for the second line treatment of metastatic breast cancer; Enobosarm + abemaciclib, a combination versus estrogen blocking agent as secondary treatement of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.